Marker Therapeutics, Inc. (NASDAQ:MRKR) Short Interest Update

Marker Therapeutics, Inc. (NASDAQ:MRKR) was the target of a significant increase in short interest in September. As of September 15th, there was short interest totaling 226,620 shares, an increase of 62.8% from the August 31st total of 139,192 shares. Currently, 1.4% of the shares of the stock are sold short. Based on an average daily volume of 67,897 shares, the short-interest ratio is presently 3.3 days.

Marker Therapeutics Stock Performance

Marker Therapeutics stock traded down $0.03 during trading hours on Wednesday, reaching $1.07. 35,195 shares of the company’s stock traded hands, compared to its average volume of 149,828. The firm has a market capitalization of $17.92 million, a price-to-earnings ratio of -2.62 and a beta of 1.53. Marker Therapeutics has a fifty-two week low of $0.84 and a fifty-two week high of $2.46. The firm’s 50 day moving average is $1.22 and its 200-day moving average is $1.36.

Marker Therapeutics (NASDAQ:MRKR) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.16. Marker Therapeutics had a negative net margin of 343.03% and a negative return on equity of 56.96%. Analysts predict that Marker Therapeutics will post -0.64 EPS for the current year.

Analyst Ratings Changes

MRKR has been the topic of several research reports. Weiss Ratings raised Marker Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, September 18th. HC Wainwright reissued a “buy” rating on shares of Marker Therapeutics in a research note on Friday, August 21st. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Marker Therapeutics has an average rating of “Hold” and an average price target of $10.00.

Institutional Trading of Marker Therapeutics

An institutional investor recently bought a new position in Marker Therapeutics stock. Concurrent Investment Advisors LLC purchased a new position in Marker Therapeutics, Inc. (NASDAQ:MRKR) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 67,963 shares of the company’s stock, valued at approximately $100,000. Concurrent Investment Advisors LLC owned about 0.41% of Marker Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 22.39% of the company’s stock.

About Marker Therapeutics

Marker Therapeutics, Inc (NASDAQ: MRKR) is a clinical-stage biotechnology company focused on developing cell therapies for cancer. The company’s approach uses multiTAA-specific T cells, which are designed to recognize and attack multiple tumor-associated antigens rather than a single target. Marker Therapeutics is developing these therapies for patients with solid tumors and certain hematologic malignancies.

The company’s lead investigational product, MT-601, is an autologous multiTAA-specific T-cell therapy being evaluated in clinical development, including for pancreatic cancer.